Markets:

Overview

News

Currencies

International

Treasuries

Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

3.650 -0.030 (-0.82%)

Streaming Delayed Price Updated: 1:46 PM EDT, Jul 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Fulcrum Therapeutics, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 10, 2023

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2023 ↗

March 10, 2023

Via Benzinga

United Airlines To Rally Around 54%? Here Are 10 Other Analyst Forecasts For Friday ↗

March 10, 2023

Piper Sandler raised the price target for Riskified Ltd. (NYSE: RSKD) from $6 to $8. Piper Sandler analyst Brent Bracelin upgraded the stock from Neutral to Overweight. Riskified shares rose 2.4% to...

Via Benzinga

Fulcrum Therapeutics's Earnings Outlook ↗

March 08, 2023

Via Benzinga

What 6 Analyst Ratings Have To Say About Fulcrum Therapeutics ↗

February 27, 2023

Via Benzinga

Why JD.com Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

March 09, 2023

Gainers

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

March 09, 2023

Via Benzinga

Dow Up 150 Points; US Weekly Jobless Claims Rise ↗

March 09, 2023

U.S. stocks traded higher this morning, with the Dow Jones gaining around 150 points on Thursday. Following the market opening Thursday, the Dow traded up 0.46% to 32,948.78 while the NASDAQ rose 0.27%...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

March 09, 2023

Via Benzinga

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

March 09, 2023

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ET

March 06, 2023

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

FULCRUM ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulcrum Therapeutics, Inc. on Behalf of Fulcrum Stockholders and Encourages Investors to Contact the Firm

March 03, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Fulcrum Therapeutics, Inc. (FULC) Investigation

March 02, 2023

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors

March 02, 2023

From Glancy Prongay & Murray LLP

Via Business Wire

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Fulcrum Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

March 02, 2023

From The Schall Law Firm

Via Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors

March 01, 2023

From Law Offices of Howard G. Smith

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Fulcrum Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

March 01, 2023

From The Schall Law Firm

Via Business Wire

The Law Offices of Frank R. Cruz Announces Investigation of Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors

March 01, 2023

From The Law Offices of Frank R. Cruz

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023 ↗

February 28, 2023

Via Benzinga

uniQure To Rally Around 162%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

February 28, 2023

UBS cut the price target for Honeywell International Inc. (NASDAQ: HON) from $193 to $185. UBS analyst Chris Snyder maintained a Sell rating. Honeywell shares fell 0.2% to $191.99 in pre-market...

Via Benzinga

Dow Dips 350 Points; S&P 500 Down Over 1% ↗

February 24, 2023

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 300 points on Friday. The Dow traded down 1.07% to 32,798.91 while the NASDAQ fell 1.90% to 11,370.53. The S&P 500...

Via Benzinga

Why Fulcrum Therapeutics Shares Are Trading Lower By Over 55%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

February 24, 2023

Gainers Bridger Aerospace Group Holdings, Inc. (NASDAQ: BAER) shares jumped 129.6% to $10.15. Jeffrey E. Kelter reported a 22.4% stake in a 13D filing on Thursday.

Via Benzinga

Stocks Extend Slump, Head For Weekly Losses ↗

February 24, 2023

Stocks are extending their premarket losses, with the Dow Jones Industrial Average down 409 points.

Via Talk Markets

12 Health Care Stocks Moving In Friday's Intraday Session ↗

February 24, 2023

Via Benzinga

Nasdaq Tumbles 2%; Timber Pharmaceuticals Shares Spike Higher ↗

February 24, 2023

U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 450 points on Friday. The Dow traded down 1.39% to 32,692.94 while the NASDAQ fell 2.14% to 11,342.36. The S&P 500 also...

Via Benzinga

FDA Slams Break On Fulcrum Therapeutics' Sickle Cell Disease Study, Shares Plummet ↗

February 24, 2023

Via Benzinga

Fulcrum Therapeutics (FULC) Stock Plummets 55% on Clinical Hold News ↗

February 24, 2023

FULC stock is falling fast today due to a regulatory issue, but Fulcrum Therapeutics remains committed to combating sickle cell disease.

Via InvestorPlace

US Stocks Open Lower; Dow Drops 1% ↗

February 24, 2023

U.S. stocks traded lower this morning, with the Dow Jones dropping over 150 points on Friday. Following the market opening Friday, the Dow traded down 1.05% to 32,807.33 while the NASDAQ fell 1.52% to...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

February 24, 2023

Via Benzinga

Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease

February 24, 2023

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.